Roth Capital Analysts Cut Earnings Estimates for Biofrontera

Biofrontera Inc. (NASDAQ:BFRI) – Equities research analysts at Roth Capital lowered their FY2029 earnings per share estimates for Biofrontera in a research note issued to investors on Monday, May 19th. Roth Capital analyst J. Aschoff now anticipates that the company will earn $0.82 per share for the year, down from their prior forecast of $0.89. The consensus estimate for Biofrontera’s current full-year earnings is ($3.01) per share.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.33). Biofrontera had a negative net margin of 36.31% and a negative return on equity of 565.73%. The firm had revenue of $8.59 million for the quarter, compared to analyst estimates of $10.55 million.

Separately, Benchmark dropped their price target on shares of Biofrontera from $7.00 to $2.75 and set a “buy” rating on the stock in a research note on Monday.

Biofrontera Stock Performance

NASDAQ:BFRI opened at $0.66 on Tuesday. The company has a market capitalization of $6.22 million, a P/E ratio of -0.29 and a beta of 0.37. The stock’s 50 day moving average price is $0.79 and its 200 day moving average price is $0.94. Biofrontera has a 52 week low of $0.62 and a 52 week high of $2.22.

Institutional Trading of Biofrontera

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rosalind Advisors Inc. raised its stake in shares of Biofrontera by 63.9% in the 4th quarter. Rosalind Advisors Inc. now owns 811,918 shares of the company’s stock valued at $885,000 after acquiring an additional 316,428 shares in the last quarter. AIGH Capital Management LLC boosted its position in Biofrontera by 61.8% during the fourth quarter. AIGH Capital Management LLC now owns 811,097 shares of the company’s stock worth $884,000 after purchasing an additional 309,663 shares during the period. Finally, Virtu Financial LLC acquired a new position in Biofrontera during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.